🚨Trade Alert 🚨 $VMCS

🚨Trade Alert 🚨 $VMCS͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ This little-known healthcare technology company has the potential to be multi-bagger for investors, as they’re quietly taking the healthcare industry by storm…. Welcome readers, As we enter 2023 many investors are wondering how they could possibly be optimistic about where the market is heading. However, the truth is, the current economic downturn has presented immense opportunity for investors who are able to uncover well-run businesses in industries that remain steady (or will even experience an increase in demand) when a recession hits. The healthcare industry is expected to reach a valuation of $780 billion by 2030 according to [Verified Market Research]( implying a compound annual growth rate of 8.7% in that time span. Healthcare is an integral part in modern society. And as the world population continues to age, the demand for improved healthcare services will become even more important. Additionally, the demand for healthcare services will persist regardless of any macroeconomic headwinds. With this backdrop in mind, brings our attention to a rapidly up-and-coming small cap business that is drastically improving how healthcare facilities deliver their services. Currently trading at $0.0057, InnovaQor (VMCS) has a truly unique suite of healthcare software designed to streamline operations, increase safety, and ensure the sustained growth of healthcare facilities. InnovaQor’s technology provides their users with the ability to cut costs through an infrastructure-related management software, leverage data in new ways, improve service with a best-in-class patient lifecycle management system, innovate with a turn-key laboratory information system (LIS), and fully customize a patient’s drug therapy plan with ease. Healthcare firms save millions of lives every year and require best-in-breed backend software to support their life saving initiatives. Many healthcare facilities have extremely complex processes, operate at lightning fast speeds, and as a result, have a high margin for error when operations aren’t managed properly. The reality of the healthcare industry is there is zero room for error when saving lives. This is also the exact reason why InnovaQor – through their innovative suite of healthcare tech solutions – is poised to see phenomenal growth in 2023 and beyond. The global healthcare market was valued at $359 billion in 2022, with US national healthcare expenditures reaching [$4.3 trillion in 2021]( (equating to $12,914 per American) and should reach a whopping $6.2 trillion by 2028. The healthcare industry is demanding significant technological innovation as the needs of healthcare providers continues to increase. InnovaQor, with a market cap of only $1.5 million and trading at only 2 times sales is primed for a BULLISH move upwards in 2023 as the company is beginning to become a favorite amidst a variety of different healthcare facilities. Now is a great opportunity for investors to add this small cap to their watchlists before they get the inevitable recognition from the rest of Wall Street. []( COMPANY OVERVIEW Approximately $15M of investment prior to acquisition by InnovaQor Acquired by InnovaQor in 2021 Fully reporting SEC Company 2022 Plans to roll out products and increase revenue 2023 Will pursue synergistic acquisitions with additional revenue 2023 Should qualify for up-listing to Nasdaq in 24-36 months InnovaQor (VMCS) has developed a suite of software technology specifically designed to help a variety of different healthcare facilities improve their operations. The company has created an easy-to-use stack which allows users to better treat patients while simultaneously improving profitability. InnovaQor strongly believes there is a substantial gap in the healthcare industry. Currently, hospitals, treatment centers, and many other healthcare businesses rely on confusing, complex, and fragmented software to run their operations. InnovaQor is working to fix this problem through offering multiple different software solutions that scale to the needs of the client and provide users an intuitive and cost-effective way of managing their workload. From overseeing operations, managing patients, creating analytical dashboards, or changing a patient’s drug therapy plan, InnovaQor makes completing these tasks easier and faster, all while reducing costs. Their suite of products also allows for a comprehensive customer acquisition strategy which should lead to sustained revenue growth as they continue to build out their sales strategy. STRONG RATINGS InnovaQor has multiple bullish ratings, most notably from [investing.com]( which is showing a BUY indication based off technical analysis. InnovaQor’s moving averages are aligning for a large move upwards as the stock is beginning to gain recognition from both retail and institutional investors. INNOVAQOR TECHNOLOGY It’s difficult to provide a comprehensive overview of the technology InnovaQor provides, however think of it like this. Ensuring systems are running properly and healthcare providers can treat patients requires an incredible amount of back-end technology a patient would never see. Typically, this technology requires a large in-house staff to ensure IT systems are functioning properly and issues are troubleshooted appropriately. This is not only costly, but also an inefficient way to run a business. InnovaQor’s software suite is a cloud-based system that provides facilities with the critical software they need to deliver their services – without the large maintenance costs or extensive IT department. From overseeing a facilities hardware and software assets to creating financial reports to managing multi-location clinical locations, InnovaQor is a true one-stop-shop for any modern healthcare facility. Their tech is completely cloud-based, 100% scalable to the needs of the client, and works seamlessly with other healthcare related tech. In short, InnovaQor supports all stages of the healthcare process and combines the customer service side of healthcare with data analytics – allowing their users to improve operational efficiency, ultimately leading to a facility’s sustainable growth and superior profit margins. PRIMED FOR EXPONENTIAL REVENUE & SHARE PRICE GROWTH In their most recent quarter InnovaQor reported topline revenue of $0.08 million with an improving gross margin of 62.50%. The company is beginning to enter their primary growth stage, and as such, should experience improving revenue, as well as better cash-flow generation, return on equity, and a growing bottom line. Further, analysts are expecting top-line growth of 467% in 2023 and 467% in 2024. This should be accompanied with near positive cash-flow and continuously improving profit margins. Below is just one forecast for where InnovaQor’s share price is expected to go: With an ending share price of over $0.70 by 2025, would be a gain of over 17,555% from current levels. With the current share price and revenue growth estimates being a base case, the opportunity for greater gains remains much higher. IN SUMMARY The healthcare industry is certainly not new, rather healthcare spending surpassed $4.3 trillion in 2021, showcasing just how engrained this industry has become in modern day economies. And while this may not be an exciting new market to penetrate, healthcare is an industry that is ripe for disruption. InnovaQor is pioneering in the healthcare technology market and is poised to see significant growth in the coming quarters and years. The stock trades at only, $0.0057, giving it a market cap of barely more than $1 million. If it were to retake it’s 52 week high, it would be a 76% gain. And if conservative estimates are met it would be a 17,000% gain!! The BULLISH thesis on InnovaQor is only picking up steam, and it won’t be long until this stock gains the attention of Wall Street. Both fundamental and technical analysis is showing InnovaQor is a STRONG BUY at current levels. This company has unlimited upside at current levels and should be at the top of every investor’s watchlist. ________________________________________________________________________ Copyright 2022 © SCDalerts.com is owned and operated by the owner of SCD Media LLC. Disclaimer and Privacy For more Information please contact info@smallcapsdaily.com This website provides information about the stock market and other investments. This website does not provide investment advice and should not be used as a replacement for investment advice from a qualified professional. This website is for informational purposes only. The Author of this website is not a registered investment advisor and does not offer investment advice. You, the reader, bear responsibility for your own investment decisions and should seek the advice of a qualified securities professional before making any investment. Nothing on this website should be considered personalized financial advice. Any investments recommended here in should be made only after consulting with your personal investment advisor and only after performing your own research and due diligence, including reviewing the prospectus or financial statements of the issuer of any security. SCD Media, its managers, its employees, affiliates, and assigns (collectively "The Company") do not make any guarantee or warranty about the advice provided on this website or what is otherwise advertised above. To the maximum extent permitted by law, the Company disclaims all liability in the event any information, commentary, analysis, opinions, advice and/or recommendations provided herein prove to be inaccurate, incomplete, or unreliable, or result in any investment or other losses. You received this message as part of your subscription to SCD Alerts. SCD Alerts is a free financial news and information website. We do not directly sell any products or offer any personal financial advice, nor do we advocate the purchase or sale of any security or investment for any specific individual. We also do not make any guarantee or warranty about what is advertised above. If you have questions or concerns about a product you’ve seen in one of our emails, we encourage you to reach out to that company directly. Disclaimer – Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated, and edited by SCD Media. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” or “SCD” refers to SCD Media. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore unqualified to give investment recommendations. Companies with low prices per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares, we will list the information relevant to the stock and the number of shares here. We do not own any shares in VMCS. We have been currently compensated Five Thousand Dollars Cash ($5,000) via bank wire transfer from a third-party Tradigital IR LLC for a 1 Day Marketing Program regarding VMCS with a start date of 1/25/2023. SCD’s business model is to receive financial compensation to promote public companies. This compensation is a major conflict of interest in our ability to be unbiased regarding our alerts. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, SCD often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. No longer want to receive these emails? [Unsubscribe](. Small Caps Daily 1334 Northampton St Easton, PA 18042